Jayamas Medica Industri TBK PT OMED.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

166

+2.47%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in IDR, from our data supplier.

FY2025

Revenue

IDR 2.06trn

FY2019FY2025

Net income

IDR 366.95bn

FY2019FY2025

Free cash flow

IDR 279.19bn

FY2019FY2025

Shareholders' equity

IDR 2.72trn

FY2019FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	IDR 2.06trn	IDR 1.89trn	IDR 1.74trn	IDR 1.74trn	IDR 2.23trn	IDR 1.99trn	IDR 1.23trn
Gross profit	IDR 695.09bn	IDR 623.98bn	IDR 552.00bn	IDR 563.07bn	IDR 904.29bn	IDR 1.04trn	IDR 445.47bn
Research and development	—	—	—	—	—	IDR 715.1m	IDR 514.7m
Operating income	IDR 386.38bn	IDR 348.47bn	IDR 302.56bn	IDR 378.95bn	IDR 734.46bn	IDR 854.21bn	IDR 3.33bn
Net income	IDR 366.95bn	IDR 321.67bn	IDR 259.36bn	IDR 285.78bn	IDR 562.69bn	IDR 685.51bn	IDR 226.21bn
Diluted earnings per share	13.58	11.89	10.36	10.56	20.80	25.33	8.36

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total assets	IDR 3.20trn	IDR 2.83trn	IDR 2.58trn	IDR 2.51trn	IDR 1.73trn	IDR 1.42trn	IDR 662.07bn
Cash and short-term investments	IDR 1.34trn	IDR 1.31trn	IDR 1.18trn	IDR 1.33trn	IDR 837.84bn	IDR 697.03bn	IDR 316.21bn
Total liabilities	IDR 445.08bn	IDR 329.64bn	IDR 336.07bn	IDR 437.90bn	IDR 480.96bn	IDR 466.01bn	IDR 476.9m
Debt	IDR 216.11bn	IDR 185.53bn	IDR 189.23bn	IDR 199.70bn	IDR 186.67bn	IDR 165.33bn	IDR 2.27bn
Shareholders' equity	IDR 2.72trn	IDR 2.46trn	IDR 2.22trn	IDR 2.04trn	IDR 1.22trn	IDR 938.86bn	IDR 561.41bn
Shares outstanding	27,024m	27,059m	25,029m	27,059m	27,059m	27,059m	27,059m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Cash from operations	IDR 395.08bn	IDR 351.57bn	IDR 134.35bn	IDR 92.62bn	IDR 505.11bn	IDR 278.73bn	IDR 174.72bn
Capital spending	−IDR 115.89bn	−IDR 102.34bn	−IDR 156.39bn	−IDR 75.37bn	−IDR 82.78bn	−IDR 52.45bn	−IDR 14.49bn
Free cash flow	IDR 279.19bn	IDR 249.23bn	−IDR 22.03bn	IDR 17.25bn	IDR 422.32bn	IDR 226.29bn	IDR 160.22bn
Dividends paid	−IDR 96.55bn	−IDR 77.93bn	−IDR 85.78bn	−IDR 250.00bn	−IDR 255.00bn	—	—

Latest quarters

By quarter end

	Jun 2026	Mar 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024
Revenue	IDR 594.55bn	IDR 572.25bn	IDR 593.92bn	IDR 544.05bn	IDR 489.53bn	IDR 436.32bn	IDR 521.33bn	IDR 484.85bn
Gross profit	IDR 206.44bn	IDR 199.64bn	IDR 214.15bn	IDR 179.80bn	IDR 165.89bn	IDR 146.88bn	IDR 177.01bn	IDR 154.91bn
Operating income	IDR 119.77bn	IDR 109.66bn	IDR 120.78bn	IDR 102.99bn	IDR 86.89bn	IDR 82.45bn	IDR 110.40bn	IDR 73.07bn
Net income	IDR 121.07bn	IDR 98.37bn	IDR 112.74bn	IDR 100.48bn	IDR 80.97bn	IDR 72.76bn	IDR 110.75bn	IDR 66.98bn
Diluted earnings per share	4.48	3.64	4.17	3.72	3.00	2.69	4.09	2.48
Cash from operations	IDR 100.27bn	IDR 43.27bn	IDR 155.75bn	IDR 74.60bn	IDR 61.26bn	IDR 103.47bn	IDR 109.61bn	IDR 77.63bn
Capital spending	−IDR 27.57bn	−IDR 12.58bn	−IDR 69.19bn	−IDR 19.52bn	−IDR 16.07bn	−IDR 11.11bn	−IDR 42.00bn	−IDR 14.98bn
Free cash flow	IDR 72.70bn	IDR 30.69bn	IDR 86.56bn	IDR 55.08bn	IDR 45.19bn	IDR 92.36bn	IDR 67.61bn	IDR 62.64bn
Total assets	IDR 3.41trn	IDR 3.32trn	IDR 3.20trn	IDR 3.03trn	IDR 2.84trn	IDR 2.94trn	IDR 2.83trn	IDR 2.74trn
Cash and short-term investments	IDR 1.42trn	IDR 1.37trn	IDR 1.34trn	IDR 1.29trn	IDR 1.16trn	IDR 1.37trn	IDR 1.31trn	IDR 1.24trn
Debt	IDR 232.99bn	IDR 233.41bn	IDR 244.60bn	IDR 215.55bn	IDR 31.00bn	IDR 190.91bn	IDR 185.53bn	IDR 180.36bn
Shareholders' equity	IDR 2.83trn	IDR 2.82trn	IDR 2.72trn	IDR 2.61trn	IDR 2.52trn	IDR 2.53trn	IDR 2.46trn	IDR 2.35trn

Financial ratios

Data as of 26 Aug 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Gross margin	33.7%	33.1%	31.8%	32.4%	40.6%	52.0%	—
Operating margin	18.7%	18.5%	17.4%	21.8%	33.0%	42.8%	—
Net margin	17.8%	17.1%	14.9%	16.4%	25.3%	34.4%	—
Return on equity	13.5%	13.1%	11.7%	14.0%	46.0%	73.0%	—
Return on assets	11.5%	11.4%	10.0%	11.4%	32.6%	48.4%	—
Free cash flow yield	8.2%	7.3%	5.1%	2.7%	—	—	—
Revenue growth	9.4%	8.6%	-0.1%	-21.9%	11.6%	62.4%	—
Earnings growth	14.1%	24.0%	-9.2%	-49.2%	-17.9%	203.0%	—
Current ratio	10.36x	7.66x	15.04x	9.15x	5.46x	4.79x	—
Debt to equity	0.08x	0.07x	0.08x	0.09x	0.14x	0.17x	—
Equity ratio	85.1%	87.1%	85.9%	81.5%	70.9%	66.3%	—
Interest coverage	21.61x	17.80x	15.59x	18.35x	33.83x	94.83x	—
R&D as a share of sales	—	—	—	—	—	0.0%	0.0%
Buybacks as a share of market value	0.1%	-8.1%	7.5%	—	—	—	—

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	5.9%	0.7%	—
Operating income	0.6%	-14.7%	—
Net income	8.7%	-11.7%	—

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	33.4%	32.8%	37.6%	—
Operating margin	18.6%	19.1%	25.8%	—
Net margin	17.4%	16.6%	21.3%	—

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022
Price to earnings	15.2	15.1	20.6	20.1
Price to sales	2.7	2.6	3.1	3.3

Dividends and splits

Per share, in the currency the company pays

Paid for 3 years. Last went ex-dividend on 18 Jun 2026.

	FY2026	FY2025	FY2024	FY2023
Paid in the year	4.08	3.57	2.88	3.17

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Jayamas Medica Industri TBK PT OMED.JK · IDR

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology